Q1 Earnings Estimate for CATX Issued By HC Wainwright

Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) - Research analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Perspective Therapeutics in a report released on Monday, May 19th. HC Wainwright analyst R. Burns forecasts that the company will earn ($0.32) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $10.00 target price on the stock. The consensus estimate for Perspective Therapeutics' current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Perspective Therapeutics' FY2026 earnings at ($1.24) EPS.

Other equities analysts have also recently issued reports about the company. Royal Bank of Canada reduced their target price on Perspective Therapeutics from $16.00 to $15.00 and set an "outperform" rating on the stock in a research note on Thursday, March 27th. Scotiabank assumed coverage on shares of Perspective Therapeutics in a report on Friday, March 7th. They issued a "sector outperform" rating and a $15.00 price objective for the company. Truist Financial cut their target price on shares of Perspective Therapeutics from $10.00 to $8.00 and set a "buy" rating on the stock in a research note on Wednesday, May 14th. Wedbush restated an "outperform" rating and issued a $11.00 price objective on shares of Perspective Therapeutics in a report on Tuesday, May 13th. Finally, Cantor Fitzgerald raised Perspective Therapeutics to a "strong-buy" rating in a research report on Tuesday, March 4th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $12.50.

Perspective Therapeutics Stock Performance

CATX stock traded down $0.12 during midday trading on Tuesday, hitting $2.39. The company had a trading volume of 656,911 shares, compared to its average volume of 1,037,451. Perspective Therapeutics has a 52 week low of $1.60 and a 52 week high of $16.55. The stock's 50 day moving average price is $2.24 and its 200 day moving average price is $3.32.

Hedge Funds Weigh In On Perspective Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CATX. Y Intercept Hong Kong Ltd purchased a new stake in shares of Perspective Therapeutics during the 4th quarter valued at about $33,000. Aigen Investment Management LP purchased a new stake in Perspective Therapeutics in the fourth quarter worth approximately $34,000. National Bank of Canada FI grew its position in Perspective Therapeutics by 549,900.0% in the 4th quarter. National Bank of Canada FI now owns 11,000 shares of the company's stock worth $35,000 after purchasing an additional 10,998 shares during the period. ProShare Advisors LLC grew its holdings in shares of Perspective Therapeutics by 49.1% in the fourth quarter. ProShare Advisors LLC now owns 15,225 shares of the company's stock worth $49,000 after acquiring an additional 5,011 shares during the period. Finally, Vontobel Holding Ltd. purchased a new stake in Perspective Therapeutics during the fourth quarter valued at $51,000. 54.66% of the stock is owned by institutional investors.

Insider Activity at Perspective Therapeutics

In other news, Director Robert F. Williamson III acquired 22,192 shares of Perspective Therapeutics stock in a transaction on Friday, March 28th. The stock was acquired at an average cost of $2.27 per share, for a total transaction of $50,375.84. Following the purchase, the director now owns 70,837 shares in the company, valued at $160,799.99. This trade represents a 45.62% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Juan Graham bought 33,333 shares of the company's stock in a transaction dated Friday, March 28th. The stock was purchased at an average price of $2.25 per share, for a total transaction of $74,999.25. Following the purchase, the chief financial officer now owns 35,354 shares of the company's stock, valued at approximately $79,546.50. This represents a 1,649.33% increase in their position. The disclosure for this purchase can be found here. Insiders purchased a total of 115,696 shares of company stock valued at $256,344 in the last 90 days. Corporate insiders own 3.72% of the company's stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.